× Key messages Background Findings Perspectives Expert commentary

Efficacy and safety of AXS-07 in acute migraine

Key messages

  • Over 70% of patients are not fully satisfied with their current treatments, mainly due to suboptimal efficacy, and 80% would try a new therapy.
  • Ineffective acute treatment may contribute to medication overuse, chronification of migraine and poor long-term outcomes.
  • AXS-07 treatment resulted in rapid, sustained, substantial and statistically significant efficacy compared to rizatriptan, meloxicam and placebo.
  • AXS-07 provided significant benefit to patients with acute migraine and a history of inadequate response to prior treatments, even in patients with difficult-to-treat migraines.